---
title: "Moleculin market study shows strong physician, payer interest in Annamycin for R/R AML"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288863149.md"
description: "Moleculin Biotech reported independent research indicating strong interest in Annamycin for relapsed/refractory AML. Oncologists gave a 6/7 likelihood-to-prescribe score, driven by complete remissions, MRD-negative responses, and transplant-bridging potential. Key advantages include biomarker-agnostic applicability, combination therapy potential, and reduced cardiotoxicity allowing repeat dosing. Payers and administrators view it as a compelling value proposition for broad patient populations."
datetime: "2026-06-05T12:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288863149.md)
  - [en](https://longbridge.com/en/news/288863149.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288863149.md)
---

# Moleculin market study shows strong physician, payer interest in Annamycin for R/R AML

**Moleculin reported independent research showing physicians averaged a 6/7 likelihood to prescribe Annamycin in relapsed/refractory AML.**

**Key Highlights:**

-   Independent survey found oncologists' average likelihood-to-prescribe score for Annamycin of 6 out of 7.
-   Physicians cited complete remissions, MRD-negative responses and transplant-bridging potential as drivers of interest.
-   Biomarker-agnostic applicability and potential to combine with targeted therapies noted as clinical advantages.
-   Reduced cardiotoxicity seen as key differentiator enabling possible repeat dosing, important for pediatric and adult care.
-   Payers and hospital administrators indicated Annamycin could offer a compelling value proposition for a broad R/R AML population.

Original SEC Filing: Moleculin Biotech, Inc. \[ MBRX \] - 8-K - Jun. 05, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)

## Related News & Research

- [Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment | MBRX Stock News](https://longbridge.com/en/news/288725004.md)
- [Syndax Presents New Data For Revuforj In Treating Leukemia, Records 90% OS In AML Patients](https://longbridge.com/en/news/288589220.md)
- [Taiho Oncology Announces New England Journal of Medicine Publication of First All-Oral Regimen in Newly Diagnosed Acute Myeloid Leukemia](https://longbridge.com/en/news/288633148.md)
- [18:13 ETFrom Bystanders to Heart Savers: MedStar Health CPR Training Event Puts Power to Save Lives in Community's Hands](https://longbridge.com/en/news/288941241.md)
- [BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease](https://longbridge.com/en/news/288931357.md)